It’s a cautious thumbs-up from a Medicare coverage advisory committee for Dendreon’s prostate cancer drug Provenge. The committee, made up of health industry experts, doctors and researchers, found enough evidence to support the use of Provenge for late-stage prostate-cancer patients whose disease has metastasized, but not for those prostate cancer patients whose cancer hasn’t progressed.

The recommendation is . . . → Read More: Medicare Committee Recommends Payment for Provenge for Some Prostate Cancer Patients